Dermatofibroma screening: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 31: | Line 31: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Primary care]] | |||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Revision as of 13:41, 11 June 2019
Dermatofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dermatofibroma screening On the Web |
American Roentgen Ray Society Images of Dermatofibroma screening |
Risk calculators and risk factors for Dermatofibroma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]
References